Rofecoxib Analogues Possessing a Nitric Oxide Donor Sulfohydroxamic Acid (SO2NHOH) Cyclooxygenase‐2 Pharmacophore: Synthesis, Molecular Modeling, and Biological Evaluation as Anti‐inflammatory Agents

No abstract is available for this paper.

• Publication year

  2012

• Venue

  ChemMedChem

• Publication date

  2012-01-02

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/cmdc.201100393PMID 21990143
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms of Cyclooxygenase-2 Inhibition and Cardiovascular Side Effects—The Plot Thickens

  2009cited by this paper
• New celecoxib derivatives as anti-inflammatory agents.

  2008cited by this paper
• Chemical and biological investigation of N-hydroxy-valdecoxib: An active metabolite of valdecoxib.

  2008cited by this paper
• A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors.

  2004cited by this paper
• Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties.

  2003cited by this paper
• Design and synthesis of novel rofecoxib analogs as potential cyclooxygenase (COX-2) inhibitors: Replacement of the methylsulfonyl pharmacophore by a sulfonylazide bioisostere

  2003cited by this paper
• Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.

  2002cited by this paper
• Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human.

  2002cited by this paper
• Risk of cardiovascular events associated with selective COX-2 inhibitors.

  2001cited by this paper
• 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.

  2000cited by this paper
• The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

  1999cited by this paper
• Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).

  1997cited by this paper
• Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

  1996cited by this paper
• Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2

  1996cited by this paper
• Oxidative release of nitric oxide accounts for guanylyl cyclase stimulating, vasodilator and anti-platelet activity of Piloty's acid: a comparison with Angeli's salt.

  1995cited by this paper
• The physiological role of nitric oxide

  1993cited by this paper
• Carrageenin-Induced Edema in Hind Paw of the Rat as an Assay for Antiinflammatory Drugs

  1962cited by this paper

• The chemistry of HNO-releasing compounds

  2024cites this paper
• Exploring Nitric Oxide (NO)-Releasing Celecoxib Derivatives as Modulators of Radioresponse in Pheochromocytoma Cells

  2022cites this paper
• Design, synthesis, in vitro determination and molecular docking studies of 4-(1-(tert-butyl)-3-phenyl-1H-pyrazol-4-yl) pyridine derivatives with terminal sulfonamide derivatives in LPS-induced RAW264.7 macrophage cells

  2021cites this paper
• Evaluation of the Inhibitory Effects of Pyridylpyrazole Derivatives on LPS-Induced PGE2 Productions and Nitric Oxide in Murine RAW 264.7 Macrophages

  2021cites this paper
• Screening of NO Inhibitor Release Activity from Soft Coral Extracts Origin Palu Bay, Central Sulawesi, Indonesia

  2019cites this paper
• Transition-metal-free regioselective construction of 1,5-diaryl-1,2,3-triazoles through dehydrative cycloaddition of alcohols with aryl azides mediated by SO2F2.

  2019cites this paper
• Inhibitory effects of triarylpyrazole derivatives on LPS-induced nitric oxide and PGE2 productions in murine RAW 264.7 macrophages.

  2019cites this paper
• Copper-catalyzed decarboxylative regioselective synthesis of 1,5-disubstituted 1,2,3-triazoles.

  2018cites this paper
• Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases.

  2017cites this paper
• In situ click chemistry generation of cyclooxygenase-2 inhibitors

  2017cites this paper
• Synthesis of New Tricyclic and Tetracyclic Fused Coumarin Sulfonate Derivatives and Their Inhibitory Effects on LPS‐Induced Nitric Oxide and PGE2 Productions in RAW 264.7 Macrophages: Part 2

  2016cites this paper
• A Series of COX‐2 Inhibitors Endowed with NO‐Releasing Properties: Synthesis, Biological Evaluation, and Docking Analysis

  2016cites this paper
• Pyrimidine-based fluorescent COX-2 inhibitors: synthesis and biological evaluation.

  2016cites this paper
• Dual evaluation of some novel 2-amino-substituted coumarinylthiazoles as anti-inflammatory–antimicrobial agents and their docking studies with COX-1/COX-2 active sites

  2014cites this paper
• Synthesis of new ibuprofen derivatives with their in silico and in vitro cyclooxygenase-2 inhibitions.

  2014cites this paper
• Synthesis, bioassay studies, and molecular docking of novel 5-substituted 1H tetrazoles as cyclooxygenase-2 (COX-2) inhibitors

  2014cites this paper
• Do nitric oxide-releasing drugs offer a potentially new paradigm for the management of cardiovascular risks in diabetes?

  2014cites this paper
• Synthesis of 5-alkoxy-4-amino-3-bromo-2(5H)-furanones containing benzene rings

  2013cites this paper
• Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker.

  2013cites this paper
• Can nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks?

  2013cites this paper
• Facile Oxidative Rearrangements Using Hypervalent Iodine Reagents

  2012cites this paper
• N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: synthesis and biological evaluation.

  2012cites this paper
• Cardiovascular Properties of a Nitric Oxide Releasing Rofecoxib Analogue: Beneficial Anti‐hypertensive Activity and Enhanced Recovery in an Ischemic Reperfusion Injury Model

  2012cites this paper
• Designing Multitarget Anti‐inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists–COX‐2 Inhibitors

  2012cites this paper